Shionogi Grows Rare Disease Portfolio with $2B IntraBio Acquisition

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 06 Oct, 19:53 UTC

Shionogi signaled its intent to focus on rare disease drugs in April when it acquired Radicava (edaravone), an amyotrophic lateral sclerosis (ALS) treatment, from Tanabe Pharma for $2.5 billion and potential royalties. The post Shionogi Grows Rare Disease Portfolio with $2B IntraBio Acquisition…

businessscience

Sources

• T2Shionogi Grows Rare Disease Portfolio with $2B IntraBio AcquisitionFierce Biotech / Fierce Healthcare / MedCity / GEN06 Oct, 19:53